Patury Carine Bispo, Santos Brenda Luanny Maia, Matos Anna Lucia Carvalho, Slabi José, Gastalho Luciene Cristina Campos, Kaneto Carla Martins
Department of Health Science, Universidade Estadual de Santa Cruz, Ilhéus 45662-900, BA, Brazil.
Department of Biological Science, Universidade Estadual de Santa Cruz, Ilhéus 45662-900, BA, Brazil.
Biomolecules. 2024 Dec 11;14(12):1580. doi: 10.3390/biom14121580.
Breast cancer is highly heterogeneous disease in which different responses are observed to the same treatment for different subtypes and extents of similar diseases. Considering this scenario, the search for tumor biomarkers is indispensable, with current evidence suggesting that circulating microRNAs are viable biomarkers. This study evaluated the expression of miR-21, miR-221, miR-195, and miR-451 in patients with breast cancer undergoing neoadjuvant treatment at oncology outpatient facilities in Brazil.
We conducted a prospective and observational study in which blood samples were collected for microRNA expression analysis, comparing control and breast cancer patients who were candidates for neoadjuvant treatment groups. The expression of microRNAs was investigated by qRT-PCR method. For parametric data analysis, one-way ANOVA with Tukey's post hoc test was used.
Thirty-three participants (all female) were included in the control group and twenty-seven participants were included in the study group. The non-special subtype of breast cancer was found in 96% of the study group participants; 88.9% were locally advanced tumors (T3, T4), 40.7% were luminal tumors, 33.3% were HER-2-positive, and 26% were triple negative tumors. Expression analysis of microRNAs during neoadjuvant treatment, using miR-16 as a normalizer, showed higher expression levels of miR-21 and miR-221 at the end of treatment, and high expression levels for miR-451 were also observed at the beginning of treatment.
This is the first study that evaluates the expression of microRNAs in the context of neoadjuvant treatment of breast cancer in the Brazilian population. Our results suggest that there is a deregulation of miR-21, miR-221, and miR-451 during neoadjuvant treatment in these patients.
乳腺癌是一种高度异质性疾病，对于不同亚型和相似疾病不同程度的患者，针对相同治疗会观察到不同反应。考虑到这种情况，寻找肿瘤生物标志物必不可少，目前有证据表明循环微RNA是可行的生物标志物。本研究评估了在巴西肿瘤门诊接受新辅助治疗的乳腺癌患者中miR-21、miR-221、miR-195和miR-451的表达。
我们进行了一项前瞻性观察研究，收集血样进行微RNA表达分析，比较对照组和新辅助治疗候选乳腺癌患者组。通过qRT-PCR方法研究微RNA的表达。对于参数数据分析，使用单因素方差分析和Tukey事后检验。
对照组纳入33名参与者（均为女性），研究组纳入27名参与者。研究组96%的参与者为非特殊亚型乳腺癌；88.9%为局部晚期肿瘤（T3、T4），40.7%为管腔型肿瘤，33.3%为HER-2阳性，26%为三阴性肿瘤。以miR-16作为标准化物，在新辅助治疗期间对微RNA进行表达分析，结果显示治疗结束时miR-21和miR-221表达水平较高，治疗开始时也观察到miR-451表达水平较高。
这是第一项在巴西人群中评估乳腺癌新辅助治疗背景下微RNA表达的研究。我们的结果表明，这些患者在新辅助治疗期间miR-21、miR-221和miR-451存在失调。
